Cargando…
A case of cabozantinib therapy leading to complete remission for massive intra-intestinal bleeding and worsening metastatic sites following nivolumab and ipilimumab therapy
A woman in her 50s had recurrent renal cell carcinoma six years after nephrectomy. The patient was treated with nivolumab plus ipilimumab therapy starting in May 2022. She was rushed to hospital due to melena and severe anemia in September 2022. CT showed massive leakage of contrast medium into the...
Autores principales: | Ishida, Kyohei, Hasegawa, Go, Ikeda, Yohei, Hara, Noboru, Nishiyama, Tsutomu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641597/ https://www.ncbi.nlm.nih.gov/pubmed/37965124 http://dx.doi.org/10.1016/j.eucr.2023.102603 |
Ejemplares similares
-
Cabozantinib/ipilimumab/nivolumab interaction: Haemophagocytic lymphohistiocytosis: case report
Publicado: (2021) -
Complete remission following pembrolizumab therapy for a patient with
nephroureterectomy positive-margin carcinoma in situ and bladder cancer unresponsive to
Bacille Calmette–Guérin therapy
por: Nakamura, Ryohta, et al.
Publicado: (2023) -
Primary lung cancer treatable with radical resection after complete remission with pembrolizumab therapy following gemcitabine and carboplatin chemotherapy for multiple metastases of bladder cancer
por: Nakamura, Ryohta, et al.
Publicado: (2022) -
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
por: Apolo, Andrea B., et al.
Publicado: (2020) -
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
por: Yau, Thomas, et al.
Publicado: (2023)